Tags

Type your tag names separated by a space and hit enter

Florbetapir F 18 for brain imaging of β-amyloid plaques.
Drugs Today (Barc). 2013 Mar; 49(3):181-93.DT

Abstract

Recent trends in neurodegeneration research have been aimed at developing new amyloid ligands for the neuroimaging of dementia. Among the positron emission tomography (PET) radiotracers, fluorodeoxyglucose F 18 ((18)F-FDG) is the compound most widely used in the diagnosis of neurodegenerative dementias. However, this compound shows a level of specificity and sensitivity for early Alzheimer's disease detection that is lower than that provided by high-affinity ligands for β-amyloid (Aβ). Among the new widely available fluorine 18 ((18)F)-labeled Aβ ligands, florbetapir F 18 ((18))F-AV-45; Amyvid™) showed clear qualitative and quantitative correlations between in vivo PET imaging and postmortem histopathologic analysis of Aβ. Florbetapir F 18 stands out for its high Aβ affinity and its pharmacokinetic properties that allow 10-minute PET scan imaging within 90 minutes after administration (dose = 370 MBq). Importantly, no safety concerns for florbetapir F 18 were found in preclinical studies. In 2012, the U.S. Food and Drug Administration (FDA) approved Amyvid as a radiotracer helpful for excluding the presence of Aβ in the brain. It was then approved earlier this year by the European Medicines Agency (EMA).

Links

Publisher Full Text

Authors+Show Affiliations

Romano M
Department of Life Sciences, University of Trieste, Trieste, Italy. mromano@units.it
Buratti E
No affiliation info available

MeSH

Alzheimer DiseaseAniline CompoundsAnimalsBrainClinical Trials as TopicDrug ApprovalEthylene GlycolsHumansPlaque, AmyloidPositron-Emission TomographyRadiopharmaceuticalsSensitivity and SpecificityTime FactorsUnited StatesUnited States Food and Drug Administration

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23527322

Citation

Romano, M, and E Buratti. "Florbetapir F 18 for Brain Imaging of Β-amyloid Plaques." Drugs of Today (Barcelona, Spain : 1998), vol. 49, no. 3, 2013, pp. 181-93.
Romano M, Buratti E. Florbetapir F 18 for brain imaging of β-amyloid plaques. Drugs Today (Barc). 2013;49(3):181-93.
Romano, M., & Buratti, E. (2013). Florbetapir F 18 for brain imaging of β-amyloid plaques. Drugs of Today (Barcelona, Spain : 1998), 49(3), 181-93. https://doi.org/10.1358/dot.2013.49.3.1937428
Romano M, Buratti E. Florbetapir F 18 for Brain Imaging of Β-amyloid Plaques. Drugs Today (Barc). 2013;49(3):181-93. PubMed PMID: 23527322.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Florbetapir F 18 for brain imaging of β-amyloid plaques. AU - Romano,M, AU - Buratti,E, PY - 2013/3/26/entrez PY - 2013/3/26/pubmed PY - 2013/6/26/medline KW - AV-45 KW - Alzheimer's disease KW - Cognitive decline KW - Contrast media KW - Diagnostic agents KW - Florbetapir F 18 KW - Radiopharmaceuticals KW - Ultrasound contrast agents SP - 181 EP - 93 JF - Drugs of today (Barcelona, Spain : 1998) JO - Drugs Today (Barc) VL - 49 IS - 3 N2 - Recent trends in neurodegeneration research have been aimed at developing new amyloid ligands for the neuroimaging of dementia. Among the positron emission tomography (PET) radiotracers, fluorodeoxyglucose F 18 ((18)F-FDG) is the compound most widely used in the diagnosis of neurodegenerative dementias. However, this compound shows a level of specificity and sensitivity for early Alzheimer's disease detection that is lower than that provided by high-affinity ligands for β-amyloid (Aβ). Among the new widely available fluorine 18 ((18)F)-labeled Aβ ligands, florbetapir F 18 ((18))F-AV-45; Amyvid™) showed clear qualitative and quantitative correlations between in vivo PET imaging and postmortem histopathologic analysis of Aβ. Florbetapir F 18 stands out for its high Aβ affinity and its pharmacokinetic properties that allow 10-minute PET scan imaging within 90 minutes after administration (dose = 370 MBq). Importantly, no safety concerns for florbetapir F 18 were found in preclinical studies. In 2012, the U.S. Food and Drug Administration (FDA) approved Amyvid as a radiotracer helpful for excluding the presence of Aβ in the brain. It was then approved earlier this year by the European Medicines Agency (EMA). SN - 1699-3993 UR - https://www.unboundmedicine.com/medline/citation/23527322/Florbetapir_F_18_for_brain_imaging_of_β_amyloid_plaques_ L2 - http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=1937428 DB - PRIME DP - Unbound Medicine ER -